Part one: API selection
This is a three part series that will be presented live within 2 different time zones. Check the link at the bottom of the page to read up on part two and three of this comprehensive series.
As drug molecules become increasingly complex, solid form characterization can provide drug development scientists with the insights they need to accelerate the development of new pharmaceutical products.
In this three-part webinar series, experts from Netzsch and Malvern Panalytical will use real-life case studies to show you the analytical techniques that make active pharmaceutical ingredient (API) candidate selection process more productive.
The first session will focus on API selection. Join us as our experts chart the path from candidate molecule synthesis to lead candidate selection, using a range of thermal and structural solid form characterization techniques
Discover why chemistry acumen is vital for successful drug discovery. Find out how ADME (Absorption, Distribution, Metabolism, and Excretion) testing of hundreds of molecules synthesized by skilled chemists allows the analysts to select most promising candidates. Learn how applying a multi-technique approach provides the most robust mechanism for selecting lead candidates. Understand how to detect even slightest changes that can put performance of manufactured drug substance/product at risk.
You will also have the option to ask questions to our experts, Dr Gabriele Kaiser, Dr David Fengas and Dr Natalia Dadivanyan.
Join our upcoming series of "Everything pharmaceutical scientists need to know about solid form characterization"
- Webinar 1: API selection
- Webinar 2: Formulation and Process Development. Register here
- Webinar 3: Characterizing amorphous materials. Register here
Speakers
- Dr. Gabriele Kaiser - Business Field Manager Pharmacy, Cosmetics and Food at Netzsch
- Dr. David Fengas - Director of CMC services, Concept Life Sciences
- Dr. Natalia Dadivanyan - Field Application Scientist X-ray Products, Malvern Panalytical
More information
Who should attend?
- Anyone involved in stability studiesAnyone engaged in chemical development or support of scale up activities
- Anyone engaged in polymorph screening activities as part of lead optimization activities
- Anyone who is developing pharmaceutical formulations